August J. Troendle, President and CEO of Medpace Holdings, Inc. (NASDAQ:MEDP), filed a Form 4 on August 31, 2026, reporting the sale of 650 shares of common stock on August 27, 2026.
Key Highlights
- Shares sold: Troendle disposed of 650 shares of Medpace Holdings common stock on August 27, 2026.
- Weighted average price: The reported sale price was $620.27 per share, a weighted average across multiple transactions ranging from $620.00 to $621.28.
- Direct holdings after sale: Troendle directly owns 539,894 shares of common stock following the reported transaction.
- Indirect holdings: Troendle also indirectly holds 4,733,019 shares through Medpace Investors, LLC, of which he is the sole manager and controlling unit holder.
- Transaction basis: The sale was effected pursuant to a limit order placed during an open window period, according to the filing.
Troendle's Sale Details and Ownership Structure at Medpace Holdings
According to the Form 4 filing, Troendle sold 650 shares of Medpace Holdings common stock on August 27, 2026, using transaction code "S." The filing states the reported price of $620.27 is a weighted average, with individual transactions occurring in a range from $620.00 to $621.28. The filing notes that Troendle undertakes to provide full pricing information to the issuer, any security holder, or SEC staff upon request.
The filing discloses that the transactions were effected pursuant to a limit order placed by Troendle during an open window period. Following the sale, Troendle directly owns 539,894 shares. In addition, the filing reports 4,733,019 shares held indirectly through Medpace Investors, LLC. The filing states that Troendle is the sole manager and controlling unit holder of that entity and has "sole voting and investment control with respect to the securities held by MPI." The filing further notes that Troendle "may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."
The Form 4 was signed by Stephen P. Ewald as Attorney-in-Fact for August J. Troendle and filed on August 31, 2026. Troendle is identified in the filing as a director, officer (President and CEO), and 10% owner of Medpace Holdings, Inc.
What Was Disclosed
The filing reports a single open-market sale of 650 shares of Medpace Holdings common stock by President and CEO August J. Troendle on August 27, 2026, at a weighted average price of $620.27, with direct beneficial ownership of 539,894 shares remaining after the transaction.




Please wait processing your request...